/Companies

Pharosyn

Entrepreneur First '25

London, GB · Founded 2025 · 6 employees on LinkedIn · 5 known investors

Find your way into Pharosyn

Each arrow is one introduction. Sign up to fill in the first one.

1,600 people can intro you to Joshua

Ask Ravinder Bhadhal to introduce you to Joshua Hampson

You →Ravinder · together at Intropic →Joshua

1,046 people can intro you to Stephen

Ask Jamie Chen to introduce you to Stephen Cowley

You →Jamie · together at Orbit →Stephen

Sign up to find every way you can get introduced to Pharosyn

  • Your email: who you already know at Pharosyn, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pharosyn team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Pharosyn uses AI to continuously monitor clinical trials, regulatory filings, press releases, and earnings calls, and produce strategic competitive intelligence reports on a company's competitors. It serves competitive intelligence teams at pharmaceutical and biotech organizations.

Also known as Pharosyn · Pharosyn Ltd

Founders & leadership

Pharosyn was founded in 2025 by Stephen Cowley and Joshua Hampson.

SCStephen Cowley
Stephen CowleyCo-Founder and CEOStephen studied AI at Cambridge University, finishing in the top 5% of his cohort. While still a student, he developed the earliest AI models at a neurotech startup that subsequently raised venture funding.
JHJoshua Hampson
Joshua HampsonCo-Founder & CTOJosh studied biochemistry at Cambridge University, graduating in the top 5%, and later developed AI models for drug discovery at AstraZeneca. He then spent four years heading engineering teams while the business grew from $2M to $12M in revenue, building latency-sensitive data platforms used by major hedge funds for decision-making.

Investors · 5

Also in the syndicate · 1

Transpose

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeedSep 2026 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Company profile

researched Aug 2026

Pharosyn is a London-based software company building an AI platform for biopharma competitive intelligence. The product continuously monitors clinical trials, regulatory filings, press releases and earnings call transcripts, then automatically writes strategic reports on clinical, regulatory and commercial events involving a customer's competitors. Users configure deliverables (format, structure, tone, cadence and alert thresholds), can upload existing reports so the system extracts reusable templates, and specify monitoring interests in plain language rather than query syntax; monitoring specifications update as the customer's pipeline evolves. Reports include market, clinical and regulatory impact assessments, and the company states setup to continuous insight delivery takes about 20 minutes [0][1].

Additional platform capabilities described include broader geographic coverage of clinical, regulatory and commercial news, including regional registries; unification of primary and secondary reporting on a single event into one view; an AI triaging engine that scores and ranks incoming events against pipeline criteria; and continuous automated updating of imported competitive landscape documents [0][1]. Nordic9 describes Pharosyn as a British software startup founded by Stephen Cowley and Joshua Hampson, developing an AI-powered pharmaceutical intelligence platform that unifies fragmented data into a single interface and applies domain-specific AI so research teams shift from manual data gathering to analysis [3].

Business model

B2B SaaS sold to pharmaceutical and biotech organizations [3]. Prospective customers request access and are offered a customized trial personalized to their pipeline, including full access to the monitoring and intelligence platform, coverage across clinical trials, regulatory filings, press releases and earnings calls, and dedicated support from the Pharosyn team during the trial [0][1]. Job postings refer to shipping production code to enterprise pharma clients [4][5].

Described as B2B SaaS; specific pricing is not disclosed in available sources [3].

Traction

Public evidence is limited. The website carries testimonials from David McBay (Director) and Juan Ivars, PhD (Consultant) of Eradigm Consulting describing a partnership and reduced monitoring workload [0][1]. A recruiting listing describes the company as having 2–10+ employees and hiring a founding AI engineer at £100k–£150k plus equity in London [5][4].

Latest developments

Nordic9 reported on 16 October 2025 that Pharosyn raised a pre-seed round with investors Entrepreneur First and Transpose; round value and total investment were not disclosed [2][3]. A founding AI engineer role in London remained open with an application window running to 2 September 2026 [4][5]. The company also operates a second web domain, pharosyn.ai, with identical site content [1].

▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies

Market position

Early-stage (pre-seed) company backed by Entrepreneur First, positioned as an automated alternative to manual competitive intelligence monitoring and reporting in the regulated pharma industry [2][4][5]. Nordic9 categorizes it under AI, competitive intelligence, pharma and software services verticals with a B2B SaaS model [3].

Positions on plain-language monitoring specification instead of query syntax, automatic coverage of hard-to-reach geographies and regional registries, unification of all reporting on a single event, AI-based event prioritization against a customer's pipeline, automatic maintenance of imported competitive landscape documents, and source-traceable AI outputs with enterprise governance controls [0][1].

Technology

An LLM-based system with orchestration layers and data pipelines that continuously ingest clinical trials, regulatory filings, press releases and earnings call transcripts, plus an AI triaging engine that scores and ranks events against customer pipeline criteria [0][1][4][5]. The stack is described as full-stack Python, TypeScript and React [4][5]. Governance claims include privacy-first processing in secure cloud environments, SOC 2 aligned infrastructure, AES-256 encryption at rest, TLS-encrypted connections, customer data excluded from model training, outputs traceable to underlying source documents, use of established foundation models for inference only with pinned and tracked model versions, and role-based access control with project/resource scoping and row-level security [0][1].

Go-to-market

Direct enterprise sales via website "Request Access" and customized trials tailored to a prospect's pipeline [0][1], supported by a stated partnership with Eradigm Consulting, a competitive intelligence consultancy whose staff appear as references on the site [0][1].

Competitive intelligence, strategy and research teams within pharmaceutical and biotech organizations, including enterprise pharma clients; the company also references a partnership relationship with consultancy Eradigm Consulting, whose director and a consultant provide testimonials [0][1][4][5].

Geography

Headquartered in London, United Kingdom, with offices listed as London; product coverage is described as extending into additional geographies and regional registries [3][4][5][0][1].

History

Founded by Stephen Cowley and Joshua Hampson as a British software startup based in London [3]; backed by Entrepreneurs First and described as pre-seed in 2025–2026 recruiting materials [4][5].

Risks & controversies

No controversies are reported in the available sources. Notable risk factors visible from the material are early stage and undisclosed funding amounts [2][3], a small team [5], reliance on third-party foundation models [0][1], and security posture described as "SOC 2 aligned" rather than certified [0][1]. Note that a similarly named entity, PharmaCorp Rx Inc., is unrelated.

Compiled by commissioned research from 9 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Advertised founding AI engineer salary rangeJan 2026£100,000–£150,000 plus equity
Disclosed round valueOct 2025Not disclosed (N/A)
Employee countJan 20252-10+ employees
Employee count (range as listed by recruiter profile)Jan 20262–10+ employees
Open positionsJan 20252 roles
Stated time from setup to continuous strategic insightsJan 202620 minutes

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Timeline · 4

launches, deals, and filings
Jan 2026
Hiring founding AI engineer in London

Pharosyn posted a Founding AI Engineer role in London at £100k–£150k plus equity, working with the CTO on LLM orchestration, data pipelines and full-stack development; applications open until 2 September 2026.

source ↗

Jan 2026
Partnership with Eradigm Consulting referenced on company website

Pharosyn's website features testimonials from David McBay (Director) and Juan Ivars, PhD (Consultant) at Eradigm Consulting describing a partnership and use of Pharosyn's automated filtering and system integration.

source ↗

Oct 2025
Pharosyn raises undisclosed pre-seed round from Entrepreneur First and Transpose

Nordic9 reported Pharosyn raised pre-seed funding; round value and total investment received were listed as not available. Investors named: Entrepreneur First and Transpose.

source ↗

Oct 2025
Pharosyn raises pre-seed funding from Entrepreneur First and Transpose

Pharosyn was reported to have raised a pre-seed round backed by Entrepreneur First and Transpose; the round value was not disclosed.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Companies House · registry record

View on Companies House ↗
Registered name
PHAROSYN LIMITED
Company number
17410200
Status
Active
Company type
Private limited company
Incorporated
20 Aug 2026
Registered office
9th Floor 107 Cheapside, London, EC2V 6DN
Nature of business (SIC)
62012 — Business and domestic software development
Accounts
next due 20 May 2028
Confirmation statement
next due 2 Sept 2027

Current officers · 3

  • Ohs Secretaries Limited — corporate secretary, appointed 20 Aug 2026
  • Stephen Sergei Cowley — director, appointed 20 Aug 2026
  • Harold Joshua Hampson — director, appointed 20 Aug 2026

Source: Companies House public register · retrieved 20 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

▸Research sources · 9

primary sources listed

9 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Pharosyn do?
UK pre-seed startup using AI to generate continuous competitive intelligence reports for pharma and biotech teams.
Who founded Pharosyn?
Pharosyn was founded by Stephen Cowley, Joshua Hampson in 2025.
Who are Pharosyn's investors?
Pharosyn's investors include Entrepreneur First, Moonfire Ventures, Transpose Platform Management, General Advance.
Where is Pharosyn headquartered?
Pharosyn is headquartered in London, GB.